Volume 32, No 11, Nov 2022

ISSN: 1001-0602 
EISSN: 1748-7838 2018 
impact factor 17.848* 
(Clarivate Analytics, 2019)

Volume 32 Issue 11, November 2022: 967-968

RESEARCH HIGHLIGHTS

Fine-tuning T cell function through engineered orthogonal chimeric cytokine receptors

Rigel J. Kishton^* , Nicholas P. Restifo^*

Surgery Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
Correspondence: Rigel J. Kishton(kishtonr@gmail.com)Nicholas P. Restifo(drnickrestifo@gmail.com)

In a recent study published in Nature, Kalbasi et al. demonstrate that engineering T cells to express a chimeric orthogonal IL-2 receptor, where the intracellular domain (ICD) of the receptor was replaced with the IL-9 receptor ICD, mitigated negative impacts of IL-2 administration and also drove signaling through STAT1, STAT3 and STAT5 to promote anti-tumor function and T cell stemness.

https://doi.org/10.1038/s41422-022-00715-w

FULL TEXT | PDF

Browse 322